CliffBio
small molecule

LOTEPREDNOL ETABONATE

LOTEPREDNOL ETABONATE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameLOTEPREDNOL ETABONATE
Active ingredientLOTEPREDNOL ETABONATE
Strength0.5%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.